American Society of Hematology

SHERPA: Blue

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Park
    Park
  3. Zelenetz
    Zelenetz
  4. Chadha
    Chadha
  5. Dogan
    Dogan
  6. Owens
    Owens
  7. Roeker
    Roeker
  8. Seshan
    Seshan
  9. Stein
    Stein
  10. Thompson
    Thompson

Groups

  1. Center for Hematologic Malignancies (7)
  2. Department of Medicine (7)
  3. Executive Committee, Center for Hematologic Malignancies (7)
  4. GSK Faculty (7)
  5. Hematologic Malignancies, Division of (7)
  6. Human Oncology and Pathogenesis Program (7)
  7. Nursing (7)
  8. Tow Center for Developmental Oncology (TCDO) (7)
  9. Adult Leukemia (6)
  10. Advanced Practice Providers (3)
Search Within
  1. "Meeting abstract"
  2. "Human Oncology and Pathogenesis Program"
  3. "Omar Abdel-Wahab"
  4. "Nursing"
Formats
  1. Meeting Abstract (7)
Groups
  1. Center for Hematologic Malignancies (7)
  2. Department of Medicine (7)
  3. Executive Committee, Center for Hematologic Malignancies (7)
  4. GSK Faculty (7)
  5. Hematologic Malignancies, Division of (7)
  6. Human Oncology and Pathogenesis Program (7)

More Groups

People
  1. Omar Abdel-Wahab (7)
  2. Martin Tallman (4)
  3. Andrew Zelenetz (3)
  4. Jae Park (3)
  5. Ahmet Dogan (2)
  6. Anthony Mato (2)

More People

Years
  1. 2022 (1)
  2. 2021 (3)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (1)
Publications
  1. Blood (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Shukla, M.; Salcedo, J. M.; Vemuri, S.; Kinoshita, J. C.; Smith, M. D.; Winer, E. S.; Abdel-Wahab, O.; Tallman, M. S.
    Blood (2019)

    Fulltext@MSK | Save
  • Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents
    Meeting Abstract

    Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
    Blood (2018)

    Fulltext@MSK | Save